This complimentary live program will present information beyond diagnosis to address the significant challenges in identifying and managing PBH and congenital hyperinsulinism, with a focus on delayed diagnosis, inconsistent terminology, and gaps in clinical awareness. The program will also explore underlying pathophysiology, including dysregulated GLP-1–mediated insulin secretion, and highlight the clinical presentation and real-world burden of recurrent hypoglycemia. Emphasis will be placed on establishing clear diagnostic approaches, improving care coordination across specialties, and reviewing emerging therapeutic options, including investigational agents.
- Live Webinar Date: Friday, October 2, 2026
- Time: 1:00-2:00 PM EDT
Upon completion of the program, participants will be able to:
- Recognize the clinical presentation and diagnostic challenges of post-bariatric hypoglycemia (PBH), including differentiation from other causes of hypoglycemia and interpretation of clinical findings in patients following bariatric surgery.
- Evaluate the underlying pathophysiology and clinical consequences of PBH, including GLP-1–mediated mechanisms, symptom burden, and the impact of recurrent hypoglycemia on patient safety, functioning, and quality of life.
- Apply evidence-based and emerging management strategies for PBH through case-based development of individualized treatment plans that incorporate nutritional interventions, patient education, monitoring approaches, and evolving therapeutic options.
The primary target audience for this program is endocrinologists and the endocrine care team, including nurses, nurse practitioners (NPs), physician assistants (PAs), and diabetologists.
View All Rare Endocrine Disease Webinars
Mary Elizabeth Patti, MD
Senior Investigator and Professor of Medicine
Joslin Diabetes Center and Harvard Medical School
Boston, MA
Sangeeta Kashyap, MD
Assistant Chief of Clinical Affairs
Professor of Clinical Medicine
New York-Presbyterian/Weill Cornell Medical Center
This activity is supported by an educational grant from Amylyx Pharmaceuticals, Inc.